

# Do her risk factors require a strong start with treatment?

## Patient with newly diagnosed lupus nephritis

### Jenna R., 39-year-old patient with lupus nephritis

- Jenna was diagnosed with SLE 6 months ago
- Recent urinalysis was suggestive of lupus nephritis
  - Kidney biopsy confirmed diagnosis
- Her lab values and other clinical risk factors put her at high risk for poor long-term outcomes

Not an actual patient

SLE=systemic lupus erythematosus.

## Indications

LUPKYNIS is indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN). *Limitations of Use:* Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation.

## Important Safety Information

**BOXED WARNINGS: MALIGNANCIES AND SERIOUS INFECTIONS** – Increased risk for developing malignancies and serious infections with LUPKYNIS or other immunosuppressants that may lead to hospitalization or death.

Please see additional [Important Safety Information](#) and [Prescribing Information](#) including [Boxed Warning](#) and [Medication Guide](#) for LUPKYNIS.

 **Lupkynis**<sup>™</sup>  
(voclosporin) capsules  
7.9 mg

# Clinical history



## Jenna R., 39-year-old patient with lupus nephritis

### Recent lupus nephritis diagnosis

#### Biopsy findings at baseline

- ISN Class IV + V
- Diffuse proliferative lupus nephritis affecting 60% of glomeruli
- Diffuse thickening of glomerular capillary wall
- Subendothelial, subepithelial, and mesangial immune deposition

### SLE history

- Diagnosed 6 months prior after presenting with arthritis, malar rash, and positive serologies, along with hypertension and hyperlipidemia

### Current medications

- Hydroxychloroquine (200 mg BID)
- Prednisone (5 mg/day)
- Statin
- Angiotensin II receptor blocker

## Laboratory findings and vitals


	6 months prior	Present day
<b>UPCR (mg/mg)</b>	0.1	4.1
<b>Serum albumin (g/dL)</b>	3.4	2.5
<b>Urine microscopy</b>	No active sediment	6 RBC/HPF w/ dysmorphism and cellular casts
<b>eGFR (mL/min/1.73 m<sup>2</sup>)</b>	90	80
<b>Serum creatinine (mg/dL)</b>	0.9	1.0
<b>C3 (mg/dL)</b>	100	60
<b>C4 (mg/dL)</b>	20	8
<b>Anti-dsDNA (IU/mL)</b>	90	120
<b>BP (mmHg)</b>	130/80	120/76
<b>Weight (lbs)</b>	165	172

This is a hypothetical case study. This resource is intended to help you determine the types of patients who may be appropriate for treatment with LUPKYNIS. This representation was not designed to assess efficacy for an individual patient subgroup.

BID=twice daily; BP=blood pressure; eGFR=estimated glomerular filtration rate; UPCR=urine protein/creatinine ratio.

# LUPKYNIS™ (voclosporin) offers a strong start for superior outcomes vs standard of care (MMF + steroids) alone<sup>1,2,a</sup>

**Primary endpoint:  
complete renal response  
at Week 52<sup>b</sup>**



- Patients were 2.7x more likely to respond vs standard of care alone (OR: 2.7; 95% CI: 1.6, 4.3)
- Proteinuria reductions 2x faster than with standard of care alone<sup>c</sup>
- Efficacy achieved in the presence of low-dose steroids ( $\leq 2.5$  mg/day)
- The AURORA study included patients who were newly diagnosed as well as those who were previously treated for lupus nephritis

To learn more about how LUPKYNIS can help your patients with lupus nephritis, visit [LUPKYNISpro.com](https://www.lupkynispro.com)

<sup>a</sup>The AURORA Phase 3 trial was a randomized, double-blind, placebo-controlled trial of LUPKYNIS 23.7 mg BID in combination with MMF (target 2 g/day) and corticosteroids (n=179) vs placebo BID in combination with MMF and corticosteroids (n=178) in adults with class III or IV (alone or in combination with class V) or class V lupus nephritis. Efficacy was established on the basis of complete renal response at Week 52. Key secondary endpoints included complete renal response at Week 24, partial renal response (50% reduction in UPCR from baseline) at Weeks 24 and 52, time to UPCR  $\leq 0.5$  mg/mg, and time to 50% reduction in UPCR.<sup>1,3</sup>

<sup>b</sup>The primary efficacy endpoint of complete renal response was defined as a confirmed UPCR of  $\leq 0.5$  mg/mg; eGFR  $\geq 60$  mL/min/1.73 m<sup>2</sup> or no confirmed decrease from baseline in eGFR of  $>20\%$  or no treatment- or disease-related eGFR-associated event at time of assessment; presence of sustained, low-dose steroids ( $\leq 10$  mg prednisone from Weeks 44-52); and no administration of rescue medications. Proteinuria reduction was based on time to UPCR of  $\leq 0.5$  mg/mg.<sup>1</sup>

<sup>c</sup>Secondary endpoint in the AURORA Phase 3 trial.

MMF=mycophenolate mofetil; OR=odds ratio.

## Important Safety Information (cont.)

**CONTRAINDICATIONS:** LUPKYNIS is contraindicated in patients taking strong CYP3A4 inhibitors because of the increased risk of acute and/or chronic nephrotoxicity, and in patients who have had a serious/severe hypersensitivity reaction to LUPKYNIS or its excipients.

Please see additional **Important Safety Information** and **Prescribing Information** including **Boxed Warning** and **Medication Guide** for LUPKYNIS.

 **Lupkynis™**  
(voclosporin) capsules  
7.9 mg

## Indications

LUPKYNIS is indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN). *Limitations of Use:* Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation.

## Important Safety Information

**BOXED WARNINGS: MALIGNANCIES AND SERIOUS INFECTIONS**  
**Increased risk for developing malignancies and serious infections with LUPKYNIS or other immunosuppressants that may lead to hospitalization or death.**

**CONTRAINDICATIONS:** LUPKYNIS is contraindicated in patients taking strong CYP3A4 inhibitors because of the increased risk of acute and/or chronic nephrotoxicity, and in patients who have had a serious/severe hypersensitivity reaction to LUPKYNIS or its excipients.

### WARNINGS AND PRECAUTIONS

**Lymphoma and Other Malignancies:** Immunosuppressants, including LUPKYNIS, increase the risk of developing lymphomas and other malignancies, particularly of the skin. The risk appears to be related to increasing doses and duration of immunosuppression rather than to the use of any specific agent.

**Serious Infections:** Immunosuppressants, including LUPKYNIS, increase the risk of developing bacterial, viral, fungal, and protozoal infections (including opportunistic infections), which may lead to serious, including fatal, outcomes.

**Nephrotoxicity:** LUPKYNIS, like other calcineurin inhibitors (CNIs), may cause acute and/or chronic nephrotoxicity. The risk is increased when CNIs are concomitantly administered with drugs associated with nephrotoxicity.

**Hypertension:** Hypertension is a common adverse reaction of LUPKYNIS therapy and may require antihypertensive therapy.

**Neurotoxicity:** LUPKYNIS, like other CNIs, may cause a spectrum of neurotoxicities: severe include posterior reversible encephalopathy syndrome (PRES), delirium, seizure, and coma; others include tremor, paresthesia, headache, and changes in mental status and/or motor and sensory functions.

**Hyperkalemia:** Hyperkalemia, which may be serious and require treatment, has been reported with CNIs, including LUPKYNIS. Concomitant use of agents associated with hyperkalemia may increase the risk for hyperkalemia.

**QTc Prolongation:** LUPKYNIS prolongs the QTc interval in a dose-dependent manner when dosed higher than the recommended lupus nephritis therapeutic dose. The use of LUPKYNIS in combination with other drugs that are known to prolong QTc may result in clinically significant QT prolongation.

**Immunizations:** Avoid the use of live attenuated vaccines during treatment with LUPKYNIS. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment with LUPKYNIS.

**Pure Red Cell Aplasia:** Cases of pure red cell aplasia (PRCA) have been reported in patients treated with another CNI immunosuppressant. If PRCA is diagnosed, consider discontinuation of LUPKYNIS.

**Drug-Drug Interactions:** Avoid co-administration of LUPKYNIS and strong CYP3A4 inhibitors or with strong or moderate CYP3A4 inducers. Reduce LUPKYNIS dosage when co-administered with moderate CYP3A4 inhibitors. Reduce dosage of certain P-gp substrates with narrow therapeutic windows when co-administered.

### ADVERSE REACTIONS

The most common adverse reactions ( $\geq 3\%$ ) were glomerular filtration rate decreased, hypertension, diarrhea, headache, anemia, cough, urinary tract infection, abdominal pain upper, dyspepsia, alopecia, renal impairment, abdominal pain, mouth ulceration, fatigue, tremor, acute kidney injury, and decreased appetite.

### SPECIFIC POPULATIONS

**Pregnancy/Lactation:** May cause fetal harm. Advise not to breastfeed.

**Renal Impairment:** Not recommended in patients with baseline eGFR  $\leq 45$  mL/min/1.73 m<sup>2</sup> unless benefit exceeds risk. If used in this population, reduce LUPKYNIS dose.

**Hepatic Impairment:** For mild or moderate hepatic impairment, reduce LUPKYNIS dose. Avoid use with severe hepatic impairment.

**Please see [Prescribing Information](#) including [Boxed Warning](#) and [Medication Guide](#) for LUPKYNIS.**

**References:** 1. LUPKYNIS [package insert]. Rockville, MD: Aurinia Pharma U.S., Inc., 2021. 2. Aurinia Pharma U.S., Inc. Data on file. 3. Gibson K, Parikh S, Saxena A, et al; AURORA Study Group. AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis. Presented at: National Kidney Foundation virtual 2020 Spring Clinical Meetings; March 26-29, 2020.



LUPKYNIS is a trademark of Aurinia Pharmaceuticals Inc.  
©2021 Aurinia Pharma U.S., Inc. All Rights Reserved.  
US-LUP-2100172 07/21

